Additional Proxy Soliciting Materials (definitive) (defa14a)
November 26 2019 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed
by the Registrant x
Filed
by a Party other than the Registrant ¨
Check
the appropriate box:
¨
|
Preliminary Proxy Statement
|
¨
|
Confidential, for
Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
¨
|
Definitive Proxy Statement
|
x
|
Definitive Additional
Materials
|
¨
|
Soliciting Material
Pursuant to §240.14a-12
|
Protalix BioTherapeutics, Inc.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
¨
|
Fee computed on table
below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
1)
|
Title
of each class of securities to which transaction applies:
|
|
2)
|
Aggregate
number of securities to which transaction applies:
|
|
3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
|
|
|
forth
the amount on which the filing fee is calculated and state how it was determined):
|
|
4)
|
Proposed
maximum aggregate value of transaction:
|
|
5)
|
Total
fee paid:
|
¨
|
Fee paid previously with preliminary materials.
|
¨
|
Check box if any part of the fee is offset as
provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the form or schedule and the date of its filing:
|
|
1)
|
Amount
Previously Paid:
|
|
2)
|
Form,
Schedule or Registration Statement No:
|
|
3)
|
Filing
Party:
|
|
4)
|
Date
Filed:
|
|
|
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003
P: 973.873.7700
F: 973.338.1430
www.allianceadvisors.com
|
November 25, 2019
Urgent
Re: Your Investment in Protalix Biotherapeutics Inc.
Dear Stockholder,
We have been unable to reach you regarding an important matter
relating to your investment with Protalix Biotherapeutics.
As of the date of this letter our records indicate your vote
has not yet been received for the Special Meeting of Stockholders which is scheduled to be held on December 9, 2019 and your vote
has never been more important.
The Board is pleased to announce that the two leading independent
proxy advisory firms, Institutional Shareholder Services, Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis), have recommended
that Stockholders vote FOR the reverse stock split proposal.
We strongly encourage you to vote your shares today by calling
one of our proxy specialists toll-free at 833-786-6488 between the hours of 9:00 a.m. and 10:00 p.m., Eastern Time, Monday
through Friday and Saturday and Sunday between the hours of 10:00 a.m. and 6:00 p.m., Eastern Time.
Voting only takes a few minutes. Thank you for your attention
on this matter.
Sincerely,
Melissa Carlson
Vice President
The Shareholder Communication
Strategists
Copyright © 2019 by
Alliance Advisors, LLC. ALL RIGHTS RESERVED
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024